Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients ...

The study group consisted of 22 patients with STS treated with Trabectedin (Yondelis ®, PharmaMar, Madrid, Spain), and the demographic and clinical-pathological characterization at baseline are ...